Patents by Inventor Yoshiteru Ito

Yoshiteru Ito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compound
    Patent number: 11897879
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 13, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20230322683
    Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 15, 2020
    Publication date: October 12, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masashi TOYOFUKU, Yoshiteru ITO, Marilena PIRA, Takahiro SUGIMOTO
  • Heterocyclic compound and use thereof
    Patent number: 11655241
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Yoshiteru Ito, Tohru Miyazaki, Kohei Takeuchi, Norihito Tokunaga, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Yuichi Kajita, Yuhei Miyanohana, Takahiro Sugimoto, Tatsuki Koike, Dilhumar Uyghur
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230063805
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 2, 2023
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND
    Publication number: 20230042358
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Jun CHIBA, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230040770
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: February 9, 2023
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Tatsuki KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND
    Publication number: 20230037557
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: November 26, 2020
    Publication date: February 9, 2023
    Inventors: Yoshiteru ITO, Yuhei MIYANOHANA, Yuichi KAJITA, Yasutaka HOASHI, Yasushi HATTORI, Tatsuki KOIKE, Norihito TOKUNAGA, Eiji KIMURA, Alexander Martin PAWLICZEK, Marilena PIRA, Javier MIGUELEZ-RAMOS
  • Heterocyclic compound and use thereof
    Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Fused heterocyclic compound
    Patent number: 11390634
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: July 19, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • Heterocyclic compound and application thereof
    Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220089595
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 24, 2022
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220048916
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • Heterocyclic compound
    Patent number: 11230545
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017514
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND
    Publication number: 20210332045
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210276949
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: April 23, 2021
    Publication date: September 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210198240
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: July 1, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo ODA, Yoshiteru ITO, Tohru MIYAZAKI, Kohei TAKEUCHI, Norihito TOKUNAGA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA, Yuichi KAJITA, Yuhei MIYANOHANA, Takahiro SUGIMOTO, Tatsuki KOIKE, Dilhumar UYGHUR
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20210115067
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Application
    Filed: December 22, 2020
    Publication date: April 22, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
  • Fused heterocyclic compound
    Patent number: 10981934
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 20, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA